SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,161.68 |
| Enterprise Value ($M) | 1,480.36 |
| Book Value ($M) | 738.33 |
| Book Value / Share | 10.58 |
| Price / Book | 2.93 |
| NCAV ($M) | 667.67 |
| NCAV / Share | 9.57 |
| Price / NCAV | 3.24 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.31 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.41 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 17.25 |
| Current Ratio | 17.25 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 746.89 |
| Assets | 817.55 |
| Liabilities | 79.22 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Janus Henderson Group Plc | 10.20 | 1.83 | |
| 13G/A | Price T Rowe Associates Inc /md/ | 5.50 | 3.45 | |
| 13G/A | Rtw Investments, Lp | 8.50 | 64.76 | |
| 13G/A | Alkeon Capital Management Llc | 4.80 | -11.67 | |
| 13G/A | Wellington Management Group Llp | 11.37 | 12.33 | |
| 13G/A | State Street Corp | 3.60 | -51.14 | |
| 13G | General Atlantic Llc | 7.70 | ||
| 13G/A | Pfizer Inc | 4.53 | 0.00 | |
| 13G/A | Baker Bros. Advisors Lp | 4.30 | 0.00 | |
| 13G/A | Redmile Group, LLC | 2.00 | -57.86 | |
| 13G/A | Avidity Partners Management LP | 0.40 | -93.86 | |
| 13G | Vanguard Group Inc | 5.54 | ||
| 13G/A | Adage Capital Partners Gp, L.l.c. | 0.49 | -90.19 | |
| 13G/A | BlackRock Inc. | 7.50 | 51.55 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 89,977 | 494,910 | 18.18 | |
| 47,639 | 466,658 | 10.21 | |
| 87,986 | 560,209 | 15.71 | |
| 41,177 | 477,583 | 8.62 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACT – Enact Holdings, Inc. | ADPT – Adaptive Biotechnologies Corporation |
| AGIO – Agios Pharmaceuticals, Inc. | ALEC – Alector, Inc. |
| ALKS – Alkermes plc |
Financial data and stock pages provided by
Fintel.io